Savara Inc (NASDAQ:SVRA) Receives Consensus Rating of “Moderate Buy” from Analysts

Savara Inc (NASDAQ:SVRA) has been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $9.86.

Several research firms recently weighed in on SVRA. Wells Fargo & Company initiated coverage on Savara in a report on Friday, December 20th. They issued an “overweight” rating and a $8.00 target price for the company. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price objective on shares of Savara in a report on Thursday, December 19th. HC Wainwright dropped their target price on shares of Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. Finally, Evercore ISI restated an “in-line” rating and set a $5.00 price target (down from $7.00) on shares of Savara in a report on Wednesday, November 13th.

Insider Buying and Selling

In other Savara news, CEO Matthew Pauls sold 54,702 shares of Savara stock in a transaction on Monday, December 16th. The shares were sold at an average price of $3.31, for a total transaction of $181,063.62. Following the sale, the chief executive officer now owns 1,536,379 shares in the company, valued at $5,085,414.49. The trade was a 3.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Joseph S. Mccracken acquired 20,000 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was acquired at an average price of $2.95 per share, with a total value of $59,000.00. Following the purchase, the director now owns 210,837 shares in the company, valued at approximately $621,969.15. This represents a 10.48 % increase in their position. The disclosure for this purchase can be found here. 5.13% of the stock is owned by company insiders.

Hedge Funds Weigh In On Savara

Hedge funds have recently modified their holdings of the stock. Virtu Financial LLC bought a new position in shares of Savara in the 3rd quarter valued at about $67,000. Profund Advisors LLC acquired a new position in shares of Savara during the second quarter worth $105,000. BNP Paribas Financial Markets lifted its stake in shares of Savara by 258.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company’s stock valued at $109,000 after acquiring an additional 18,534 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Savara by 14.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company’s stock valued at $112,000 after acquiring an additional 4,732 shares in the last quarter. Finally, LMR Partners LLP grew its position in Savara by 138.3% during the 3rd quarter. LMR Partners LLP now owns 36,800 shares of the company’s stock worth $156,000 after acquiring an additional 132,900 shares during the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Savara Stock Down 4.5 %

Savara stock opened at $2.75 on Friday. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13. Savara has a 1-year low of $2.60 and a 1-year high of $5.70. The firm’s fifty day simple moving average is $3.17 and its 200-day simple moving average is $3.80. The company has a market capitalization of $471.95 million, a P/E ratio of -6.40 and a beta of 0.68.

Savara (NASDAQ:SVRA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11). Sell-side analysts forecast that Savara will post -0.45 earnings per share for the current fiscal year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.